Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy (ExCell)
This study is currently recruiting participants.
Study NCT00469729   Information provided by Gamida Cell -Teva Joint Venture Ltd.
First Received: May 3, 2007   Last Updated: November 15, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hematologic Malignancies
Acute Myeloid Leukemia
Lymphoid Leukemia
Chronic Myeloid Leukemia
Hodgkin's Disease
Non-Hodgkin's Lymphoma
Myelodysplastic Syndromes
Additional conditions recognized in this trial
Hematologic Neoplasms
Hodgkin Disease
Leukemia
Leukemia, Lymphoid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Lymphoma
Lymphoma, Non-Hodgkin
Neoplasms
Preleukemia
Syndrome
More general conditions related to this trial
Bone Marrow Diseases
Disease
Hematologic Diseases
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Myeloproliferative Disorders
Neoplasms by Histologic Type
Neoplasms by Site
Pathologic Processes
Precancerous Conditions
Interventions listed in this trial
StemEx®
Sponsors listed in this trial
Gamida Cell -Teva Joint Venture Ltd.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services